An experimental CAR-T called arlo-cel improved response rates in patients with relapsed and refractory multiple myeloma who had received at least four previous therapies.
CAR-T therapy has revolutionized blood cancer treatment, particularly in multiple myeloma. But an ongoing concern remains: If patients’ cancers progress after receiving CAR-T, what other …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
Specific CAR T-cell subgroup could make lower-dose cancer therapy more effective
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could…
Lymphoma-free survival exceeding 5 years in early recipients of the cellular therapy
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas…
VIDEO: CAR-T in the frontline setting, other promising areas of research in myeloma
In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, highlights upcoming clinical trials in multiple…
